Last reviewed · How we verify
Elobromol (MITOLACTOL)
Elobromol (generic name: MITOLACTOL) is a mitolactol drug. It is currently in Phase 3 development.
Elobromol works by inhibiting cellular processes, although the exact target and mechanism are unknown.
Elobromol, also known as MITOLACTOL, is a small molecule drug in the mitolactol class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting cellular processes. Elobromol's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic. Further research is needed to fully understand its effects and potential uses. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MITOLACTOL |
|---|---|
| Drug class | mitolactol |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Think of it like a key that fits into a lock, but instead of unlocking a door, it blocks a specific process that cells use to function. This can be helpful in treating certain conditions, but it's a complex process that needs more research to fully understand. By blocking this process, elobromol may be able to slow down or stop the progression of a disease.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elobromol CI brief — competitive landscape report
- Elobromol updates RSS · CI watch RSS
Frequently asked questions about Elobromol
What is Elobromol?
How does Elobromol work?
What is the generic name of Elobromol?
What drug class is Elobromol in?
What development phase is Elobromol in?
Related
- Drug class: All mitolactol drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing